Literature DB >> 10854658

The role of costimulation in autoimmune demyelination.

M K Racke1, R B Ratts, L Arredondo, P J Perrin, A Lovett-Racke.   

Abstract

Experimental allergic encephalomyelitis (EAE) is a T cell-mediated, autoimmune disorder characterized by central nervous system (CNS) inflammation and demyelination, features reminiscent of the human disease, multiple sclerosis (MS). In addition to the signal the encephalitogenic T cell receives through the T cell receptor (TCR), a second signal, termed costimulation, is required for complete T cell activation. The B7 family of cell surface molecules expressed on antigen presenting cells (APC) is capable of providing this second signal to T cells via two receptors, CD28 and CTLA-4. Our studies have shown that costimulation provided by B7 molecules to its ligand CD28 is important in the initiation of the autoimmune response in EAE. Further, it appears the costimulation provided by B7-1 is important in disease development, while B7-2 may play an important regulatory role. We and others later showed that B7/CTLA-4 interaction plays a critical role in down-regulating the immune response. Previous work has shown that activated T cells and T cells of a memory phenotype are less dependent on costimulation than naive T cells. T cells reactive with myelin components that are involved in the pathogenesis of EAE and possibly MS would be expected to have been activated as part of the disease process. Building upon our prior work in the EAE model, we have tested the hypothesis that myelin-reactive T cells, which are relevant to the pathogenesis of CNS inflammatory demyelination, can be distinguished from naive myelin-reactive T cells by a lack of dependence upon costimulation for activation and that the costimulatory requirements of these myelin-reactive T cells change during the course of disease. Our studies in the EAE model have also addressed the mechanisms of extrathymic (peripheral) T cell tolerance following intravenous (i.v. ) administration of high dose antigen. It is believed that TCR signaling in the absence of costimulation is a vital component of peripheral tolerance mechanisms. However, recent evidence suggests that peripheral tolerance of antigen-specific T cells induced in vivo may require CTLA-4 engagement of the tolerized T cells. We have begun to examine the molecular mechanisms of tolerance induction following intravenous and intraperitoneal administration of myelin antigens in the EAE model and test the hypothesis that tolerance induction is dependent on the B7:CD28/CTLA-4 pathway. The results from our studies will enhance our understanding of the role that myelin-reactive T cells may play in the pathogenesis of MS. We have determined that MBP-reactive T cells in MS patients are less dependent upon CD28 costimulation than in normal controls, suggesting that these T cells were previously primed in vivo. Characterization of these CD28-independent myelin-specific T cells will have broad implications for a variety of immunologically based therapies in diseases such as MS.

Entities:  

Mesh:

Year:  2000        PMID: 10854658     DOI: 10.1016/s0165-5728(00)00230-7

Source DB:  PubMed          Journal:  J Neuroimmunol        ISSN: 0165-5728            Impact factor:   3.478


  14 in total

1.  Differential levels of resistance to disease induction and development of relapsing experimental autoimmune encephalomyelitis in two H-2b-restricted mouse strains.

Authors:  Jinzhu Li; Xiaoqing Zhao; Robert Skoff; Michael K Shaw; Harley Y Tse
Journal:  J Neuroimmunol       Date:  2011-04-11       Impact factor: 3.478

2.  Development of experimental autoimmune encephalomyelitis critically depends on CD137 ligand signaling.

Authors:  Julia M Martínez Gómez; J Ludovic Croxford; Kim Pin Yeo; Véronique Angeli; Herbert Schwarz; Stephan Gasser
Journal:  J Neurosci       Date:  2012-12-12       Impact factor: 6.167

3.  Lessons learned from studies of natural resistance in murine experimental autoimmune encephalomyelitis.

Authors:  Harley Y Tse; Jinzhu Li; Xiaoqing Zhao; Fei Chen; Peggy P Ho; Michael K Shaw
Journal:  Curr Trends Immunol       Date:  2012

Review 4.  Cannabinoids and neuroprotection.

Authors:  R I Grundy; M Rabuffetti; M Beltramo
Journal:  Mol Neurobiol       Date:  2001 Aug-Dec       Impact factor: 5.590

5.  Models of autoimmune demyelination in the central nervous system: on the way to translational medicine.

Authors:  Ralf A Linker; De-Hyung Lee
Journal:  Exp Transl Stroke Med       Date:  2009-10-21

6.  Role of CD28 in fatal autoimmune disorder in scurfy mice.

Authors:  Nagendra Singh; Phillip R Chandler; Yoichi Seki; Babak Baban; Mayuko Takezaki; David J Kahler; David H Munn; Christian P Larsen; Andrew L Mellor; Makio Iwashima
Journal:  Blood       Date:  2007-04-26       Impact factor: 22.113

7.  Autoantibodies to alpha-synuclein in inherited Parkinson's disease.

Authors:  Katerina K Papachroni; Natalia Ninkina; Angeliki Papapanagiotou; Georgios M Hadjigeorgiou; Georgia Xiromerisiou; Alexandros Papadimitriou; Anastasios Kalofoutis; Vladimir L Buchman
Journal:  J Neurochem       Date:  2007-05       Impact factor: 5.372

8.  Family Analysis of Linkage and Association of HLA-DRB1, CTLA4, TGFB1, IL4, CCR5, RANTES, MMP9 and TIMP1 Gene Polymorphisms with Multiple Sclerosis.

Authors:  O Yu Makarycheva; E Yu Tsareva; M A Sudomoina; O G Kulakova; B V Titov; O V Bykova; N V Gol'tsova; L M Kuzenkova; A N Boiko; O O Favorova
Journal:  Acta Naturae       Date:  2011-01       Impact factor: 1.845

Review 9.  Immunological features of alpha-synuclein in Parkinson's disease.

Authors:  Cintia Roodveldt; John Christodoulou; Christopher M Dobson
Journal:  J Cell Mol Med       Date:  2008-07-30       Impact factor: 5.310

10.  Immune profile of an atypical EAE model in marmoset monkeys immunized with recombinant human myelin oligodendrocyte glycoprotein in incomplete Freund's adjuvant.

Authors:  S Anwar Jagessar; Nicole Heijmans; Erwin L A Blezer; Jan Bauer; Robert Weissert; Bert A 't Hart
Journal:  J Neuroinflammation       Date:  2015-09-17       Impact factor: 8.322

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.